These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 19485912)

  • 1. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT).
    Zarrabeitia R; Albiñana V; Salcedo M; Señaris-Gonzalez B; Fernandez-Forcelledo JL; Botella LM
    Curr Vasc Pharmacol; 2010 Jul; 8(4):473-81. PubMed ID: 19485912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hereditary haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): a view from the 21st century.
    Begbie ME; Wallace GM; Shovlin CL
    Postgrad Med J; 2003 Jan; 79(927):18-24. PubMed ID: 12566546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to manage patients with hereditary haemorrhagic telangiectasia.
    Geisthoff UW; Nguyen HL; Röth A; Seyfert U
    Br J Haematol; 2015 Nov; 171(4):443-52. PubMed ID: 26205234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding hereditary hemorrhagic telangiectasia: From genetic anomalies to systemic manifestations, quality of life, and epistaxis management-Exploring the otolaryngologist's integral role.
    Hayama M; Maeda Y; Obata S; Tsuda T; Takeda K; Nishida T; Inohara H
    Auris Nasus Larynx; 2024 Apr; 51(2):305-312. PubMed ID: 38008660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of thalidomide therapy for refractory epistaxis in hereditary haemorrhagic telangiectasia: systematic review.
    Harrison L; Kundra A; Jervis P
    J Laryngol Otol; 2018 Oct; 132(10):866-871. PubMed ID: 30191780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local sclerotherapy with polydocanol (Aethoxysklerol®) for the treatment of Epistaxis in Rendu-Osler-Weber or Hereditary Hemorrhagic Telangiectasia (HHT): 15 years of experience.
    Morais D; Millás T; Zarrabeitia R; Botella LM; Almaraz A
    Rhinology; 2012 Mar; 50(1):80-6. PubMed ID: 22469609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integration of clinical parameters, genotype and epistaxis severity score to guide treatment for hereditary hemorrhagic telangiectasia associated bleeding.
    Beckman JD; Li Q; Hester ST; Leitner O; Smith KL; Kasthuri RS
    Orphanet J Rare Dis; 2020 Jul; 15(1):185. PubMed ID: 32660636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells.
    Albiñana V; Bernabeu-Herrero ME; Zarrabeitia R; Bernabéu C; Botella LM
    Thromb Haemost; 2010 Mar; 103(3):525-34. PubMed ID: 20135064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laser-Assisted Control of Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review.
    Abiri A; Goshtasbi K; Maducdoc M; Sahyouni R; Wang MB; Kuan EC
    Lasers Surg Med; 2020 Apr; 52(4):293-300. PubMed ID: 31441079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medical management of haemorrhagic hereditary telangiectasia in adult patients.
    Riera-Mestre A; Ribas J; Castellote J
    Med Clin (Barc); 2019 Apr; 152(7):274-280. PubMed ID: 30502301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rendu-Osler-Weber disease: experience with 56 patients.
    Sabbà C; Pasculli G; Cirulli A; Gallitelli M; Virgilio G; Guastamacchia E; Resta F; Palasciano G
    Ann Ital Med Int; 2002; 17(3):173-9. PubMed ID: 12402665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hereditary hemorrhagic telangiectasia. Genetics, pathogenesis, clinical manifestation and management.
    Stuhrmann M; El-Harith el-HA
    Saudi Med J; 2007 Jan; 28(1):11-21. PubMed ID: 17206283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osler-Weber-Rendu Syndrome in Relation to Dermatology.
    Orizaga-Y-Quiroga TL; Villarreal-Martínez A; Jaramillo-Moreno G; Ocampo-Candiani J
    Actas Dermosifiliogr (Engl Ed); 2019 Sep; 110(7):526-532. PubMed ID: 30975431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complications from office sclerotherapy for epistaxis due to hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu).
    Hanks JE; Hunter D; Goding GS; Boyer HC
    Int Forum Allergy Rhinol; 2014 May; 4(5):422-7. PubMed ID: 24431220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epistaxis in hereditary haemorrhagic telangiectasia.
    Haitjema T; Balder W; Disch FJ; Westermann CJ
    Rhinology; 1996 Sep; 34(3):176-8. PubMed ID: 8938889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): clinical manifestations and multidisciplinary management].
    Frigerio C; Aebischer N; Baud D; Bonafe L; Fellmanne F; Ikonomidis C; Mazzolai L; Michel P; Nichita C; Qanadli SD; Lazor R
    Rev Med Suisse; 2016 May; 12(517):896-901. PubMed ID: 27323484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (rendu-osler disease).
    Cottin V; Dupuis-Girod S; Lesca G; Cordier JF
    Respiration; 2007; 74(4):361-78. PubMed ID: 17641482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hereditary haemorrhagic telangiectasia.
    Sharathkumar AA; Shapiro A
    Haemophilia; 2008 Nov; 14(6):1269-80. PubMed ID: 19141168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TIMolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT) - Study protocol of the prospective, randomized, double-blind, controlled cross-over TIM-HHT trial.
    Andorfer KEC; Seebauer CT; Koller M; Zeman F; Berneburg M; Fischer R; Vielsmeier V; Bohr C; Kühnel TS
    Clin Hemorheol Microcirc; 2022; 80(3):307-315. PubMed ID: 34864649
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.